anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To easily have a permanent, and to save the time of post-treatment, by using binary system water-soluble films, which principal components are starch- protein, as end paper for a permanent wave. CONSTITUTION:The salts of the protein of casein, gelatin, etc. and alkali or alkaline earth metals are utilized as the alkali or alkaline earth metal salts of protein, and the starch of wheat, graduation amylose, etc. is used as starch group matters. 70-20 wt.% starch group matters are added to 30-80 wt.% protein group matter salts and 20-35 wt.% water is added to each of these components, granules or pellets obtained by kneading, cooling and crushing said mixture are changed into films and utilized for extrusion, inflation, etc. If using the films when having a permanent, the films rapidly contact with hair because they begin to disperse at a time when applying chemicals, and can be washed away with a shampoo, thus eliminating the need for the treatment of wastes.
Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with limited therapeutic options. Fibroblast growth factor receptor-4 (FGFR4) is a known receptor for several paracrine fibroblast growth factors (FGFs). FGFR4 is also the main receptor for FGF19, an endocrine FGF that was demonstrated by our group to have antifibrotic properties in the lung. We aimed to determine whether FGFR4 could modulate pulmonary fibrogenesis. We assessed FGFR4 mRNA and protein levels in IPF and control lungs. In vitro, we determined the effect of transforming growth factor-β (TGF-β), endothelin-1, and platelet-derived growth factor (PDGF) on FGFR4 expression in human lung fibroblasts. We determined the effect of FGFR4 inhibition, using a specific pharmacological inhibitor (FGF401), or genetic deletion in murine embryonic fibroblasts (MEFs) on TGF-β-induced myofibroblastic differentiation. In vivo, we evaluated the development of bleomycin-induced lung fibrosis in Fgfr4-deficient (Fgfr4-/-) mice compared with wild-type littermates (WT) and after FGF401 treatment in WT mice compared with a control group receiving the solvent only. FGFR4 was decreased in IPF lungs, as compared with control lungs, at mRNA and protein levels. In vitro, FGFR4 was downregulated after treatment with TGF-β, endothelin-1, and PDGF. In vitro, FGFR4 inhibition by FGF401 prevented TGF-β1-induced collagen and ACTA2 increase in lung fibroblasts. Similar results were observed in Fgfr4-/- MEFs. In vivo, FGFR4 genetic deficiency or FGFR4 pharmacological inhibition did not modulate bleomycin-induced pulmonary fibrosis. Our data suggest that FGFR4 exerts profibrotic properties by enhancing TGF-β signaling in vitro. However, the inhibition of FGFR4 is not sufficient to prevent the development of pulmonary fibrosis in vivo.NEW & NOTEWORTHY FGFR4 has been reported to have antifibrotic effects in the liver. We aimed to determine the involvement of FGFR4 during IPF. Our data suggest that FGFR4 exerts profibrotic properties by enhancing TGF-β signaling in vitro. However, the inhibition of FGFR4 is not sufficient to prevent the development of pulmonary fibrosis in vivo. To our knowledge, this is the first study to assess the profibrotic action of FGFR4 during pulmonary fibrosis.
Full hematologic evaluations should be performed before Felbamate therapy, frequently during therapy, and for a significant period of time after discontinuation of Felbamate therapy. While it might appear prudent to perform frequent CBCs in patients continuing on Felbamate, there is no evidence that such monitoring will allow early detection of marrow suppression before aplastic anemia occurs. (See Boxed Warnings). Complete pretreatment blood counts, including platelets and reticulocytes should be obtained as a baseline. If any hematologic abnormalities are detected during the course of treatment, immediate consultation with a hematologist is advised. Felbamate should be discontinued if any evidence of bone marrow depression occurs.

See Box Warnings for recommended monitoring of serum transaminases. If significant, confirmed liver abnormalities are detected during the course of Felbamate treatment, Felbamate should be discontinued immediately with continued liver function monitoring until values return to normal. (see PATIENT/PHYSICIAN ACKNOWLEDGMENT FORM).
<P>PROBLEM TO BE SOLVED: To provide a medicament inhibiting or preventing the formation of kidney stones by its binding to an oxalate.  <P>SOLUTION: Conditions such as kidney stones, which are characterized by undesired absorption of an oxalate from the intestinal tract, are conveniently treated using nontoxic salts of rare earth metal ions. A method is for controlling, preventing, or treating subjects who are at risk for or who exhibit symptoms of oxalate deposits in the kidneys, i.e., kidney stones, through the oral administration of rare earth salts, e.g. lanthanum salts, with high affinity oxalate binding properties. Preferred rare earth salts are those of yttrium, lanthanum and cerium.  <P>COPYRIGHT: (C)2009,JPO&INPIT
INTRODUCTION: The introduction of the functional lumen imaging probe (FLIP) has provided objective, real-time feedback on the geometric variations with each component of a hiatal hernia repair (HHR). The utility of this technology in altering intraoperative decision-making has been scarcely reported. Herein, we report a single-center series of intraoperative FLIP during HHR.
METHODS: A retrospective review of electronic medical records between 2020 and 2022 was conducted and all patients undergoing non-recurrent HHR with FLIP were queried. Patient and hernia characteristics, intraoperative FLIP values and changes in decision-making, as well as early post-operative outcomes were reported. Both diameter and distensibility index (DI) were measured at 40 ml and 50 ml balloon inflation after hiatal dissection, after hiatal closure, and after fundoplication when indicated.
RESULTS: Thirty-three patients met inclusion criteria. Mean age was 62 ± 14 years and mean BMI was 28 ± 6 kg/m2. The majority (53%) were type I hiatal hernias. The largest drop in DI occurred after hiatal closure, with minimal change seen after fundoplication (mean DI of 4.3 ± 2. after completion of HH dissection, vs 2.7 ± 1.2 after hiatal closure and 2.3 ± 1 after fundoplication when performed). In 13 (39%) of cases, FLIP values directly impacted intraoperative decision-making. Fundoplication was deferred in 4/13 (31%) patients, the wrap was loosened in 2/13 (15%); the type of fundoplication was altered to achieve adequate anti-reflux values in 2/13 (15%) patients, and in 1/13 (3%) the wrap was tightened.
CONCLUSION: FLIP measurements can be used intraoperatively to guide decision-making and alter management plan based on objective values. Long-term outcomes and further prospective studies are required to better delineate the value of this technology.
Patients receive capecitabine and lapatinib ditosylate as in Arm A. Patients also receive cixutumumab IV over 1 hour on days 1, 8, and 15. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
110,000 adult Chinese (35 to 74 years old) without chronic diseases and major disability who have been living in South China including Guangdong, Fujian, Guangxi and Hainan for more than 5 years will be recruited. All participants will be prospectively followed up for the incidence of chronic diseases (stroke, coronary heart disease, malignant neoplasms, chronic obstructive pulmonary diseases, diabetes and hypertension) and their risk factors (impaired glucose tolerance and obesity). Information about socio-demographic, diet, lifestyle, psychological status, medical history and current medication will be collected by questionnaires. Physical examinations including height, weight, waist and hip circumferences, blood pressure, fat mass and vital capacity will be conducted. Besides, blood, urine and fecal samples will be collected for further analysis. Annual meteorological data throughout the study period will also be collected. The associations between climate, diet and lifestyle and risks for chronic diseases will be evaluated.
The invention provides a medicine for treating hepatitis B, as well as a preparation method thereof. The medicine is formed by combining three Chinese medicines used together. The components and preparation method of a No.1 medicine are as follows: according to weight ratio, 20 grams of oriental wormwood, 15 grams of giant knotweed, 15 grams of tuckahoe, 12 grams of rhizoma alismatis, 30 grams of red sage roots, 15 grams of radix curcumae, 12 grams of bupleurum, 15 grams of oldenlandia diffusa, 15 grams of desmodiumand and 15 grams of plantain which are Chinese medicines are mixed and decocted to be decoction. The components and preparation method of a No. 2 medicine are as follows: according to weight ratio, 30 grams of hoantchy roots, 15 grams of rhizoma atractylodis macrocephalae, 15 grams of epimedium herb, 15 grams of glossy privet fruits, 20 grams of oriental wormwood, 15 grams of giant knotweed, 15 grams of tuckahoe, 12 grams of rhizoma alismatis, 30 grams of red sage roots and 15 grams of radix curcumae which are Chinese medicines are mixed and decocted to be decoction. The components and preparation method of a No. 3 medicine are as follows: hoantchy roots, rhizoma atractylodis macrocephalae, tuckahoe, bupleurum, radix curcumae, red sage roots, lithospermum, isatis roots, giant knotweed and cyrtomium rhizome which are Chinese medicines are mixed according to the weight ratio of 3:2:3:1.5:1.5:3:3:3:1.5:1.5, washed, dried, soaked for 30 minutes, pressurized and condensed into a high-density ointment on standby by use of equipment.
The invention relates to the pharmacy, in particular to the technology for manufacturing injectional dosage forms of the drugs used for preventing andtreating the coronary atherosclerosis, liver diseases, the diabetic polynephropathy, or intoxication. The method comprises mixing a-lipoic acid with organic amine, glycol, and the water for injection. N-methyl glucamine is used as an organic amine, and polyethylene glycol (PEG) is used as a glycol. According to the invention, first PEG and a-lipoic acid are mixed, and then N-methyl glucamine is added. Finally, the water for injection is added to the mixture. The specified ratio of the initial components is used for the manufacture.
This study will evaluate the interval to relapse in patients with ulcerative colitis. The patients will be adults, who have been in remission for at least one month. They will have previously required corticosteroids to induce remission. Subjects will be instructed in a no-carrageenan diet and required to follow this diet for the duration of their participation in the clinical study. They will be randomized to receive either placebo capsules or capsules containing carrageenan 100 mg. In this way, the study will be a double blind study of no-carrageenan vs. carrageenan. Main study outcome is the interval to relapse. Since ulcerative colitis is associated with relapses, relapse is anticipated. Other outcome measures will include scores on questionnaires, including the SSCAI and the SIDBQ, and laboratory measurements of inflammation.

Subjects will participate for one year or until relapse, with study visits every three months and telephone contacts every two weeks. After three months, participants will increase to two capsules daily, of either placebo or carrageenan.
Falls among people with multiple sclerosis (PwMS) are common and associated with injuries, fear of falling and low health-related quality of life. Considerations of behavioural, environmental, psychological and physical influences (including ambulation status) are needed to meet fall prevention needs for PwMS. Thus, using a codesign process involving key stakeholders a novel online self-management fall prevention intervention will be created specifically for ambulatory and non-ambulatory PwMS.

The feasibility, acceptability, fidelity and outcome of this complex intervention will be explored. Findings will inform a future full-scale randomised controlled trial. A mixed-method design will be used. Forty-eight PwMS, stratified for ambulation level, will be randomised to control (n=24) or intervention (n=24). Both groups will receive a brochure about fall risk factors and fall prevention. The intervention is group-based (eight PwMS in each group); will be delivered online; and involve six, 2-hour weekly sessions and a booster session 8 weeks after the sixth session. Each intervention group will be led by a trained facilitator.

Data collection will be performed at baseline, and after seven and 18 weeks. Outcome measures will capture data on fall prevention behaviours, fear of falling, falls self-efficacy, social and everyday activities, perceived impact of MS and number of falls. Feasibility of recruitment process, data collection procedures, outcome measures, and delivery, and intervention acceptability, fidelity and outcomes will be evaluated. Both quantitative and qualitative methods will be used.
PURPOSE:A composition for preventing and treating effectively the diarrhea of animals, prepared by incorporating an insoluble mineral adsorbent as an adsorbent and sodium polyacrylate as a membrane protecting agent in a specific proportion. CONSTITUTION:A composition for preventing and treating the diarrhea of animals, prepared by incorporating an insoluble mineral adsorbent, e.g. acid clay or china clay, and 5-25wt% based on the insoluble mineral adsorbent, sodium polyacrylate. Siliceous clay, e.g. clay from YASAWAGI in AKITA Prefecture, manufactured by Soft Silica Co., Ltd., is preferred for the acid clay. Sodium polyacrylate, e.g. ''Panakayaku F'' manufactured by Nippon Kayaku Co., Ltd. is used as the membrane protecting agent. In feeding the resultant composition to the animals, a palatable feed raw materials, e.g. a feed adsorbing soybean extract solution or defatted wheat embryo bud, etc. may be added to the above- mentioned composition. The addition of the composition in an amount of preferably 1-5wt% provides the intake of the adequate amount depending on the state of the diarrhea.
Evidence from various sources indicate that physical activities and mobility practice are beneficial to maintain or increase functional levels in persons with Multiple sclerosis. Even so persons with moderate and severe disability from Multiple sclerosis are less active in daily life than their healthy counterparts. Also during hospital stay persons with MS tend to remain relatively sedentary outside of their rehabilitation sessions. Feedback about physical activity enabled by wearable sensors combined with behavioral strategies to improve self-efficacy and motivation are potential method increase physical activity in hospital inpatients. The primary purpose of this feasibility and interventional study was to determine whether a minimalist physical activity tracker-based feedback and self efficacy training would lead to an increase in physical activity, mobility and quality of life measures during recovery in a group of persons with MS compared to a control group that does not receive feedback. Secondary purpose was to verify if this intervention during recovery would lead to increased perceived physical activity in daily home life after discharge and over longer periods (Follow up at 6 weeks). The study participants will be 60 persons that have moderate to severe disability due to MS, that are admitted to MS Centre of the Santa Maria Nascente Institute, Don Gnocchi Foundation (Milan, Italy). Participants will all receive standard rehabilitation offered in the center. All participants will wear the accelerometer device (FitBit Charge tracker, FitBit Inc, CA, USA) 24 hours per day in order to measure physical activity levels during their hospital stay (3-4 weeks. The participants will be randomized to a group that has no feedback of physical activity level and a group that will have an active feedback intervention (AF). The active feedback intervention will consist of daily feedback, received through a Fitbit application downloaded on their telephones, on whether or not their target activity level was met and how far they were from the target. Additionally, the participants will participate in weekly meeting group focused on enhancing behavioral strategies to increase self-efficacy and motivation. Covariates such as age, sex, stage of change for physical activity behavior, clinical mobility, fatigue, health perception and goal commitment will be measured in all 60 participants both pre and post the intervention/hospital recovery period. The long-term effects on daily perceived functional mobility and self-efficacy will be investigated six weeks after discharge through questionnaires during a telephone call.
BACKGROUND: Provision of effective care to all women and newborns during the perinatal period is a viable strategy for achieving the Sustainable Development Goal 3 targets on reducing maternal and neonatal mortality. This study examined perinatal care (antenatal, intrapartum, postpartum) and its association with perinatal deaths at three district hospitals in Bunyoro region, Uganda.
METHODS: A cross-sectional study was conducted in which a questionnaire was administered consecutively to 872 postpartum women before discharge who had attended antenatal care and given birth in the study hospitals. Data on care received during antenatal, labour, delivery, and postpartum period, and perinatal outcome were extracted from medical records of the enrolled postnatal women using a pre-tested structured tool. The care received from antenatal to 24 h postpartum period was assessed against the standard protocol of care established by World Health Organization (WHO). Poisson regression was used to assess the association between care received and perinatal death.
RESULTS: The mean age of the women was 25 years (standard deviation [SD] 5.95). Few women had their blood tested for hemoglobin levels, HIV, and Syphilis (n = 53, 6.1%); had their urine tested for glucose and proteins (n = 27, 3.1%); undertook an ultrasound scan (n = 262, 30%); and had their maternal status assessed (n = 122, 14%) during antenatal care as well as had their uterus assessed for contraction and bleeding during postpartum care (n = 63, 7.2%). There were 19 perinatal deaths, giving a perinatal mortality rate of 22/1,000 births (95% Confidence interval [CI] 8.1-35.5). Of these 9 (47.4%) were stillbirths while the remaining 10 (52.6%) were early neonatal deaths. In the antenatal phase, only fetal examination was significantly associated with perinatal death (adjusted prevalence ratio [aPR] = 0.22, 95% CI 0.1-0.6). No significant association was found between perinatal deaths and care during labour, delivery, and the early postpartum period.
CONCLUSION: Women did not receive all the required perinatal care during the perinatal period. Perinatal mortality rate in Bunyoro region remains high, although it's lower than the national average. The study shows a reduction in the proportion of perinatal deaths for pregnancies where the mother received fetal monitoring. Strategies focused on strengthened fetal status monitoring such as fetal movement counting methods and fetal heart rate monitoring devices during pregnancy need to be devised to reduce the incidence of perinatal deaths. Findings from the study provide valuable information that would support the strengthening of perinatal care services for improved perinatal outcomes.
PURPOSE:A removable denture, having a hydrophilic high polymer layer provided through a graft copolymer on a contact surface with an oral mucosa, capable of retaining close contact between denture base and the oral mucosa, and usable stably for a long term with slight irritancy such as pain given to the oral mucosa. CONSTITUTION:A removable denture manufactured by graft copolymerizing a monomer, e.g. (meth)acrylamide, (meth)acrylic acid, 2-hydroxyethyl (meth)acrylate or N-vinyl-2-pyrrolidone, onto a constituent material of a surface to be in contact with the mucosa in the oral cavity to form a hydrophilic high polymer layer consisting of the resultant graft copolymer. For example, a denture base consisting of a high polymer constituent material, e.g. polyurethane or polymethyl methacrylate, is subjected to the electric discharge treatment in Ar, He, H2, etc. or a mixed gas thereof to activate the above-mentioned constituent material, and the resultant denture base is then exposed to a radically polymerizable monomer to carry out graft copolymerization. The formed high polymer layer is swelled by sufficient water present in the oral cavity, and shows almost the same moisture content, flexibility elasticity, etc. as those of the oral mucosa.
QuitBet-NS will include the deposit contract and integrated CO testing with identical rules to QuitBet for being a winner, the $75 raffle for submitting at least 21 CO tests, a display of the participant's daily CO test results that is updated in real time, and a game feed on which only the game host has the ability to post. Players will not be able to post on this feed or respond to the host's posts. At the beginning of the game, the host will post limited information, including a list of smoking cessation resources. QuitBet-NS will NOT include the social feed, leaderboard, or any other social features.
A hair coloring system includes at least one component of a hair coloring product and a container configured to contain the hair coloring product. The container may include a neck having a connecting portion and a top neck end. The system may further include an applicator tip for applying the hair coloring product to hair. The applicator tip may include a base portion configured to connect the applicator tip releasably to the connecting portion of the neck of the container and a nozzle portion extending from the base portion to a top end of the tip. The applicator tip and the container may be configured such that when the applicator tip is fully connected to the connecting portion of the neck of the container, an axial length from the top neck end to the top end of the tip is greater than about 1.9 inches. In some examples, the applicator tip and the container may be configured such that a ratio of the axial length to an outer diameter of a portion of the neck including the top neck end is greater than about 1.8.
FIELD: medicine. SUBSTANCE: innovation deals with triamteren- and hydrochlorthiazide-based preparation. Triamteren is separately reduced with polyvinylpyrrolidone at 1:0.03-1:0.03-0.035 ratio, then reduced active substances are mixed with microcrystalline cellulose and additional supplements such as starch at 18- 22% amount, milk sugar at 32-37% amount and aerosil at 0.5-1.5% amount against total amount of preparation. Technical result of the present innovation is more simplified technology in obtaining the above-mentioned composition at simultaneous manufacturing simple and available tabletted form of medicinal preparation, higher tablet's strength at its simultaneous quick decomposition in water. EFFECT: improved technology. 1 ex, 1 tbl
FIELD: medicine. SUBSTANCE: method involves using pieces of skin of 0.009-0.012 mm 3 . The pieces of skin suspended in isotonic glucose solution are placed on the bottom of the wound. 12 pierces per 1 cm 2  of wound area is distributed all over wound surface. 1-4 pieces of skin are injected into one of the pierces at a depth of 3-4 mm. The wound surface is enclosed in transparent capsule insulated from environment until complete epithelialization takes place. The capsule is repeatedly refilled with sterile physiological salt solution. EFFECT: enhanced effectiveness of treatment; accelerated treatment course; large surface covered without risk of necrosis to occur.